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Abstract
Hematopoietic stem cell transplant (HSCT) is a stan-
dard treatment for many hematological malignancies. 
Three different sources of stem cells, namely bone mar-
row (BM), peripheral blood stem cells (PBSC) and cord 
blood (CB) can be used for HSCT, and each has its own 
advantages and disadvantages. Randomized controlled 
trials (RCTs) suggest that there is no significant survival 
advantage of PBSC over BM in Human Leukocyte Anti-
gen-matched sibling transplant for adult patients with 
hematological malignancies. PBSC transplant probably 
results in lower risk of relapse and hence better dis-
ease-free survival, especially in patients with high risk 
disease at the expense of higher risks of both severe 
acute and chronic graft-versus-host disease (GVHD). 
In the unrelated donor setting, the only RCT available 
suggests that PBSC and BM result in comparable overall 
and disease-free survivals in patients with hematologi-
cal malignancies; and PBSC transplant results in lower 
risk of graft failure and higher risk of chronic GVHD. 
High level evidence is not available for CB in compari-
son to BM or PBSC. The risks and benefits of different 
sources of stem cells likely change with different con-
ditioning regimen, strategies for prophylaxis and treat-
ment of GVHD and manipulation of grafts. The recent 
success and rapid advance of double CB transplant and 
haploidentical BM and PBSC transplants further compli-
cate the selection of stem cell source. Optimal selection 
requires careful weighing of the risks and benefits of 
different stem cell source for each individual recipient 
and donor. Detailed counseling of patient and donor re-
garding risks and benefits in the specific context of the 
patient and transplant method is essential for informed 
decision making.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Randomized controlled trials (RCTs) suggest no 
difference in survival between peripheral blood stem cell 
(PBSC) and bone marrow (BM) in matched sibling trans-
plant for patients with hematological malignancies. PBSC 
may result in fewer relapse in high risk patients but more 
severe graft-versus-host disease (GVHD). For unrelated 
donor, the only RCT suggests PBSC and BM result in 
comparable survivals, with PBSC resulting in fewer graft 
failure but more chronic GVHD. RCT is not available to 
compare cord blood with BM or PBSC. The risks and ben-
efits of different sources of stem cells likely change with 
transplant methods and manipulation of grafts.
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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is now 
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established as a standard therapeutic modality for a va-
riety of  malignant and non-malignant diseases. The first 
successful allogeneic HSCT was done with bone marrow 
(BM) as the source of  hematopoietic stem cells in 1968[1]. 
In the subsequent 2 decades only bone marrow was used 
as the source of  stem cells for transplantation. In the 
1960s, experiments have shown that peripheral blood 
contains a small number of  stem cells[2], which can be 
enriched by pre-treatment with certain chemotherapeutic 
drugs and hematopoietic growth factors[3-5]. Therefore 
mobilized peripheral blood stem cells (PBSC) became 
another stem cell source for HSCT and PBSC has been 
increasingly used as it has certain advantages compared 
with BM. In 1978, cord blood (CB) was found to be a 
rich source of  stem cells[6] and was later successfully used 
for allogeneic HSCT[7] at a lower cell dose infused com-
pared with BM or PBSC. 
Nowadays transplant physicians are faced with 3 vi-
able choices of  stem cells for allogeneic HSCT, namely 
BM, PBSC and CB and clinicians have to face the chal-
lenges of  selecting the optimal stem cell source. Although 
all 3 sources of  stem cells are capable of  reconstituting 
the hematopoietic system in recipient after transplant, 
they have many inherent differences in cellular constitu-
ents and biological and immunological properties. In this 
article we shall review the advantages and disadvantages 
of  different sources of  stem cells and the available clini-
cal evidence that helps clinicians to make decision. 
SELECTION AMONG DIFFERENT STEM 
CELL SOURCES
Although BM, PBSC and CB all contain hematopoietic 
stem cells, other constituents present in the harvest prod-
ucts before additional manipulation are quite different. 
Compared with unmanipulated BM, Granulocyte colony 
stimulating factor-mobilized PBSC and cord blood con-
tain significantly lower amount of  red blood cells (RBC) 
and plasma. This has certain impact on the choice of  
stem cell source when there is mismatch in blood group 
between the donor and the recipient, as harvested donor 
BM must be processed to deplete RBC or plasma or both 
before infusion to recipient. However, depletion of  RBC 
or plasma is not required for PBSC or cord blood trans-
plants even when blood group is mismatched, as the rela-
tively low amount of  RBC and RBC antibodies present in 
these products are unlikely to cause significant hemolysis. 
Another important difference among the sources of  stem 
cell is the amount of  mature T cells present. PBSC usu-
ally contains a lot more mature T cells compared to BM, 
which in turn contains more T cells compared to CB, 
and this partly explains the differences in the risk of  graft 
rejection and graft-versus-host disease (GVHD). Deple-
tion of  T cells is associated with increased risk of  graft 
rejection and disease relapse, but lower risk of  GVHD. 
The comparison of  the characteristics of  the 3 different 
sources of  stem cells is presented in Table 1. 
We often have to consider and weigh the relative ben-
efits and risks before decision on the source of  stem cells 
for allogeneic HSCT. The selection of  stem cell source is 
often intertwined with the selection of  donor. A suggest-
ed algorism for selection of  donor and stem cell source 
is given in Figure 1. One of  the basic considerations for 
allogeneic HSCT is whether a Human Leukocyte Anti-
gen (HLA)-matched related donor is available. Although 
currently results of  unrelated donor transplants of  many 
transplant centres are similar to that of  matched related 
donor transplants, the latter is still considered the first 
choice for most allogeneic HSCTs, as the donor is read-
ily available for initial donation and subsequent back-
up, and might be associated with a lower risk of  GVHD 
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Table 1  Comparison of bone marrow, peripheral blood stem cell and cord blood
BM PBSC CB
Typical time frame from initiation of search 
to transplantation
3-6 mo 3-6 mo 2-4 wk
Usual volume 500-2000 mL 50-300 mL 25-150 mL
Adverse effects for donor Risks of wound infection, bleeding, 
general anesthesia, etc.
Risks of bleeding, infection, throm-
bosis, hypotension, electrolyte 
disturbance, etc.
No
Minimal cell dose for transplant Total nucleated cell: 2 x 108/kg Total CD34+ cell: 2 x 106/kg Total nucleated cell: 2.5 x 107/kg
Red blood cell content High Low Low
Possibility to give additional stem cell dose Possible Possible Impossible
Exposure to dimethyl sulfoxide No if fresh No if fresh Yes
HLA matching requirement More stringent (7-8 out of 8 
matched)
More stringent (7-8 out of 8 
matched)
Less stringent (4-6 out of 6 
matched)
Speed of neutrophil engraftment About 3 wk About 2 wk About 4 wk
Speed of immune reconstitution Faster Faster Slower
Risk of graft-versus-host disease Medium Highest Lowest
Risk of post-transplant infections Lower Lower Higher
Risk of latent virus transmission Higher Higher Lower
Possibility of CMV  transmission Higher as most donors are CMV 
seropositive
Higher as most donors are CMV 
seropositive
Lower as most CB units do not 
harbor CMV
Risk of relapse for high risk patients Higher Lower Higher
PBSC: Peripheral blood stem cell; HLA: Human leukocyte antigen; BM: Bone marrow; CB: Cord blood; CMV: Cytomegalovirus.
and transplant-related mortality (TRM). Therefore, if  a 
matched related donor is available, the choice of  stem 
cell source is simpler and often remains BM versus 
PBSC, as related donor CB is unlikely to be available. The 
transplant physician has to weigh the risks and benefits 
to both the donor and the recipient, explain the differ-
ent procedures and experiences of  stem cell collection to 
the donor and help the donor to make informed choices. 
Clinical evidence on different outcomes of  recipients 
transplanted with BM or PBSC presented below will 
form important basis for the selection.
The donor’s perspective should be given due consid-
eration. A prospective study on donors’ experience of  
BM or PBSC donation found that before donation, BM 
donors had lower confusion, fewer concerns, and were 
more prepared for donation compared with PBSC do-
nors[8]. Shortly after donation, BM donors experienced 
more physical side effects than PBSC donors[8]. BM do-
nors also reported greater impact on their social activities, 
but had better psychological status and were more likely 
to indicate that the donation made their lives more mean-
ingful[8]. However, there were no significant longer-term 
differences between BM and PBSC donors including re-
covery time[8].
In case HLA-matched related donor CB with ad-
equate cell dose is available, relative benefits and risks 
of  CB in comparison to BM or PBSC also need to be 
considered. If  an HLA-matched related donor is not 
available; we have to find an alternative donor, the choice 
of  which often includes mismatched family donor (in-
cluding HLA-haploidentical donor), unrelated donor, or 
unrelated CB. The selection usually depends heavily on 
the urgency of  transplant, HLA matching and cell dose 
of  CB available, and preference and experience of  the 
transplant centre. Unrelated CB and mismatched family 
donor (BM or PBSC) are usually more readily available 
compared to unrelated donor and therefore if  transplant 
needs to be done urgently, CB or mismatched family 
donor is sometimes preferable. If  HSCT is not urgently 
required, unrelated donor BM or PBSC should be given 
due consideration. Since the requirement for HLA 
matching is less stringent for unrelated CB compared 
to BM or PBSC, unrelated CB is preferable to unrelated 
donor BM or PBSC if  no 7-8/8 allele-matched unrelated 
donor (or 9-10/10 allele-matched unrelated donor which 
may be associated with even lower risks of  TRM and 
GVHD) is available, provided that the CB is at least 4/6 
HLA-matched with adequate cell dose. If  there is no 
single CB with sufficient cell dose, use of  double CB can 
be considered. If  transplant is not urgently required and 
both good matched unrelated donor and unrelated CB 
with adequate cell dose are available, other considerations 
prevail, including the preference and experience of  the 
transplant centre, the patient’s disease status, the speed 
of  engraftment, risks of  infections and GVHD, age, gen-
der and location of  donor, ABO blood group matching, 
101 December 24, 2013|Volume 3|Issue 4|WJT|www.wjgnet.com
 
 
 
 
 
HLA-matched related 
donor available?
Yes No
Matched re lated 
donor BM or PBSC1 Transplant urgently needed?
NoYes
Haploidentical donor 
available?
Yes
No
Good experience with 
haploidentical HSCT?
Yes No
Haploidentical 
PBSC or BM or both1
Single or double cord 
b lood (4-6/6 HLA-
matched unrelated)
Matched unrelated 
donor BM or PBSC1
No Yes
Matched unrelated donor 
(7-8/8 or 9-10/10 HLA 
allele matched) available?
No
Figure 1  Suggested algorithm for selection of donor and source of stem cells for patients with hematological malignancies. 1Need to consider pros and cons 
of BM and PBSC in the context of donor preference, risk of relapse, conditioning regimen, graft-versus-host disease prophylaxis, and graft manipulations, etc. PBSC: 
Peripheral blood stem cell; HSCT: Hematopoietic stem cell transplant; HLA: Human leukocyte antigen; BM: Bone marrow.
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and cytomegalovirus (CMV) status, etc. If  the recipient is 
CMV seronegative, CB transplant might be preferred as 
it is less likely to transmit CMV infection and CMV sero-
negative donor might not be easily available. Good clini-
cal evidence guiding selection of  stem cells for HSCT in 
patients with hematological malignancies is summarized 
in the following section.
CLINICAL EVIDENCE FOR SELECTION OF 
STEM CELL SOURCE IN PATIENTS WITH 
HEMATOLOGICAL MALIGNANCIES
HLA-matched related donor
There were a number of  randomized controlled trials 
(RCTs) comparing PBSC and BM as stem cell source in 
transplants using HLA-matched related donor for pa-
tients with hematological malignancies. They are summa-
rized in Table 2. There were no clinical trials comparing 
HLA-matched related CB with either BM or PBSC. 
Most of  the RCTs comparing matched related donor 
BM and PBSC transplantation for patients with hema-
tological malignancies found no significant differences 
between the two stem cell source in important outcomes 
including overall survival, disease-free survival, trans-
plant-related mortality, relapse, acute GVHD and chronic 
GVHD. However, all trials showed significantly faster 
neutrophil engraftment in PBSC transplants, and all but 
one trial showed significantly faster platelet engraftment 
in PBSC transplants, which may result in earlier hospi-
tal discharge for PBSC recipients[9,10] and lower cost for 
PBSC transplantation[10]. Lymphocyte recovery was also 
found to be better in the PBSC group in one trial[9].
There was one trial showing significantly better 
overall survival at 30 mo in patients who received PBSC 
compared with BM[11]. Yet another trial showed opposite 
result, with better overall survival in BM recipients. How-
ever, in this trial CD34 selection was done before stem 
cell infusion in both BM and PBSC products and PBSC 
recipients happened to receive more CD34+ cells and T 
cells. Overall survival at 4 years was significantly worse in 
the PBSC group compared with the BM group, largely 
due to increased GVHD and TRM in PBPC recipients 
receiving T-cells greater than 2 × 105/kg. Acute GVHD 
appeared strongly associated with increased TRM. Higher 
number of  CD34+ cells was associated with less TRM. 
Some trials showed significantly higher probability of  
relapse in BM recipients than in PBSC recipients[9,12-14], 
which might translate into better disease-free survival in 
PBSC transplants compared with BM transplants[12,13]. 
The differences in disease-free survival appeared more 
pronounced among patients with higher risk malignan-
cies[12]. “High risk” or “late stage” hematological malig-
nancies usually include patients with acute leukemia in 
second or later remission, CML in blastic transformation, 
refractory anemia with excess of  blasts in transformation, 
and lymphoma heavily pretreated with chemotherapy or 
autologous transplants.
Some trials showed PBSC recipients had significantly 
more grade 2-4 acute GVHD[15-18], chronic GVHD[15-19] 
and extensive chronic GVHD[15-19] compared with BM re-
cipients, which resulted in significantly more patients who 
underwent PBPC transplant needed immunosuppressive 
treatment[18,20], and longer periods of  corticosteroid use 
and hospitalization[19]. There was no difference in perfor-
mance status, return to work, incidence of  bronchiolitis 
obliterans, hematopoietic function, and secondary malig-
nancies between the two groups in the long term in one 
trial[18]. In contrast, another trial showed that late mortal-
ity due to chronic GVHD was more frequent in PBSC 
recipients compared with BM recipients[13].
There were 2 more RCTs that included a few patients 
with severe aplastic anemia in addition to patients with 
hematological malignancies[21,22]. One small trial of  30 
patients found that PBSC transplant resulted in signifi-
cantly faster hematopoietic reconstitution, fewer days 
with neutropenic fever, shorter hospital stay and fewer 
acute GVHD (6.7% vs 46.7%)[21]. Another trial of  57 
patients found that the PBSC and the BM groups had 
similar overall survival at 18 mo (64% vs 67%), speed to 
neutrophil and platelet engraftment, and grade 2-4 acute 
GVHD (54% vs 52%)[22]. However, PBSC transplant 
resulted in significantly more steroid refractory acute 
GVHD (32% vs 0%), chronic GVHD (90% vs 47%), ex-
tensive chronic GVHD (80% vs 22%) and longer require-
ment for immunosuppressive therapy[22].
A meta-analysis of  5 RCTs[9-12,16,23] showed that PBSC 
transplant had significantly higher risk of  acute GVHD 
(RR = 1.23, 95%CI: 1.05-1.45) and chronic GVHD (RR 
= 1.37, 95%CI: 1.08-1.74) compared with BM trans-
plant[24]. A newer meta-analysis of  7 of  RCTs[9-12,16,23,25] 
showed no difference in mortality between PBSC and 
BM transplants (OR = 0.81, 95%CI: 0.62-1.05)[26]. How-
ever, mortality was significantly lower in PBSC recipients 
compared with BM recipients in studies that included 
more patients with intermediate or advanced disease (OR 
= 0.64, 95%CI: 0.45-0.91)[26]. Subgroup analysis revealed 
no significant association between mortality and CD34+ 
cell dose[26]. 
Another meta-analysis of  individual data of  1111 
patients from 9 RCTs (both published and unpublished) 
found that there was no significant difference in over-
all survival between the PBSC and the BM groups but 
disease-free survival was significantly higher in the PBSC 
group (OR = 0.80, 95%CI: 0.67-0.97)[27]. Subgroup analy-
ses showed that both overall survival (OR = 0.64, 95%CI: 
0.46-0.90) and disease-free survival (OR = 0.63, 95%CI: 
0.45-0.87) were significantly better in patients with late 
stage disease who received PBSC compared with BM[27]. 
PBSC transplant led to significantly faster neutrophil en-
graftment (OR = 0.31, 95%CI: 0.25-0.38) and platelet en-
graftment (OR = 0.52, 95%CI: 0.44-0.61) compared with 
BM transplant[27]. PBSC transplant was associated with a 
significant increase in grade 3-4 acute GVHD (OR = 1.39, 
95%CI: 1.03-1.88), chronic GVHD (OR = 1.92, 95%CI: 
1.47-2.49), and extensive chronic GVHD (OR = 1.89, 
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95%CI: 1.47-2.42), but a significant decrease in relapse 
(OR = 0.71, 95%CI: 0.54-0.93) in both late stage disease 
(OR = 0.59, 95%CI: 0.38-0.93) and early stage disease 
(OR = 0.69, 95%CI: 0.49-0.98)[27]. Non-relapse mortality 
was not significantly different between the PBSC and the 
BM groups[27]. A decision analysis based on meta-analysis 
results[27] demonstrated the superiority of  PBSC over BM 
in both overall and quality-adjusted life expectancy[28]. 
However, BM was found to be the more appropriate 
strategy if  the 1-year relapse probability was below 5%[28].
The most recent meta-analysis which included 11 
RCTs[9-11,14,18,20-22,25,29,30] found that PBSC and BM trans-
plants had comparable overall survival (HR = 1.06, 
95%CI: 0.81-1.39), disease-free survival (HR =1.04, 
95%CI: 0.83-1.30), and TRM (HR = 1.08, 95%CI: 
0.56-2.10)[31]. PBSC transplant resulted in significantly 
better neutrophil engraftment (HR = 2.08, 95%CI: 
1.80-2.42) and platelet engraftment (HR = 2.77, 95%CI: 
1.78-4.30), but significantly more grade 2-4 acute GVHD 
(HR = 0.75, 95%CI: 0.63-0.90), grade 3-4 acute GVHD 
(HR = 0.63, 95%CI: 0.47-0.84), chronic GVHD (HR = 
0.70, 95%CI: 0.59-0.83), and extensive chronic GVHD 
(HR = 0.60, 95%CI: 0.39-0.91). PBSC recipients had sig-
nificantly lower incidence of  relapse (HR = 1.91, 95%CI: 
1.34-2.74). A significant inverse relationship was observed 
between acute GVHD and overall survival.
Unrelated donor
There was an RCT comparing PBSC and BM transplants 
using HLA-matched unrelated donors after myeloabla-
tive or reduced intensity conditioning in 551 patients with 
hematological malignancies. There was no significant dif-
ference between the PBSC and the BM groups in 2-year 
overall survival (51% vs 46%), 2-year disease-free survival, 
relapse, or acute GVHD[32]. However, PBSC transplant 
resulted in significantly lower risk of  graft failure (3% vs 
9%) and higher risk of  chronic GVHD (53% vs 41%), es-
pecially extensive chronic GVHD (48% vs 32%)[32]. How-
ever, another recent non-randomized study found that 
children who received PBSC or BM did not differ sig-
nificantly in the incidence of  acute and chronic GVHD, 
which might be related to the use of  anti-thymocyte 
globulin as GVHD prophylaxis[33]. The result indicates 
that more intensive GVHD prophylaxis is required in 
PBSC transplant and this might abrogate the difference 
in GVHD risk between PBSC and BM transplants.
There was no RCT comparing unrelated CB with 
either BM or PBSC but many non-randomized compara-
tive studies were available. In a meta-analysis[34] of  10 
non-randomized clinical trials[35-44] comparing unrelated 
BM and unrelated CB for HSCT in children and adults 
with malignant and non-malignant hematological diseas-
es, it was found that BM transplant resulted in significant-
ly better overall survival (HR = 1.28, 95%CI: 1.13-1.44) 
and TRM (RR = 1.28, 95%CI: 1.03-1.58)[34]. However, 
CB transplant resulted in significantly lower grade 2-4 
acute GVHD (RR = 0.73, 95%CI: 0.64-0.82) and chronic 
GVHD (RR = 0.70, 95%CI: 0.51-0.97) compared with 
BM transplant[34]. There was no significant difference in 
the risk of  relapse.
There was a large non-randomized study not included 
in the above meta-analysis comparing unrelated CB with 
BM and PBSC in 1525 patients with acute leukemia[45]. 
Leukemia-free survival in CB transplant was comparable 
with that after 7-8/8 allele-matched BM or PBSC trans-
plant[45]. However, TRM was significantly higher after CB 
transplant than after 8/8 allele-matched BM transplant 
(HR = 1.69, 95%CI: 1.19-2.39) or PBPC transplant (HR 
= 1.62, 95%CI: 1.18-2.23)[45]. Grade 2-4 acute and chron-
ic GVHD were significantly lower in CB recipients com-
pared with 7-8/8 allele-matched PBPC recipients (HR = 
0.57, 95%CI: 0.42-0.77 and HR = 0.38, 95%CI: 0.27-0.53, 
respectively)[45]. Chronic but not acute GVHD was sig-
nificantly lower after CB transplant than after 8/8 allele-
matched BM transplant (HR = 0.63, 95%CI: 0.44-0.90)[45]. 
There was no difference among the stem cell sources in 
the rate of  relapse[45].
One comparative study performed disease-specific 
analysis of  the difference between CB transplant and BM 
transplant in 484 patients with AML and 336 patients 
with ALL after myeloablative conditioning[44]. Among 
AML patients, CB recipients had significantly lower over-
all survival (HR 1.5, 95%CI: 1.0-2.0) and leukemia-free 
survival (HR = 1.5, 95%CI: 1.1-2.0) compared with BM 
recipients[44]. TRM and relapse did not differ significant-
ly[44]. Among ALL patients, there was no significant dif-
ference between the groups in overall survival, leukemia-
free survival, TRM, and relapse[44].
Another study compared unrelated CB transplants 
with unrelated donor BM or PBSC transplants in adults 
with ALL in first or second complete remission[46]. This 
study found no significant differences in the 3-year 
overall survival between CB (44%), matched (44%) and 
mismatched (43%) unrelated donor transplants. CB 
transplants had significantly slower engraftment and less 
grade 2-4 acute but similar chronic GVHD, disease-free 
survival, TRM, and relapse[46].
OTHER IMPORTANT CONSIDERATIONS
Double cord blood
In case a single CB unit has insufficient cell dose, 2 CB 
units can be used, but both are preferably at least 4/6 
HLA-matched with the recipient and with each other, 
and together provide sufficient cell dose. Non-random-
ized studies comparing double CB transplant with single 
CB transplant in patients with hematological malignan-
cies usually found that double CB transplant was associ-
ated with higher incidence of  grade 2 acute GVHD[47-52] 
and lower incidence of  leukemia relapse[48-51,53-55], but 
there was no significant difference in overall survival, 
disease-free survival, chronic GVHD and engraftment 
times[50,52,53,56-59]. However, recently one study found 
superior overall survival and disease-free survival in ad-
dition to lower relapse in patients who received double 
CB compared with single CB transplant, although TRM 
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and chronic GVHD were not significantly different[60]. 
Double CB transplant was also found to be more cost-
effective in terms of  quality adjusted life years in adults 
with acute leukemia in first remission in France[60]. On 
the other hand, intrabone injection of  single CB might 
be associated with faster engraftment (median 23 vs 28 d) 
and lower cumulative incidence of  relapse (25% vs 29%) 
compared with intravenous double CB transplant[61].
There were some non-randomized studies compar-
ing double CB transplant with BM or PBSC transplant 
from other donors. One study on 536 patients with he-
matological malignancies transplanted with myeloablative 
conditioning found that 5-year leukemia-free survival 
was similar in double CB transplant (51%) and other 
types of  donors (either BM or PBSC), including matched 
related donor (33%), matched unrelated donor (48%), 
and mismatched unrelated donor (38%)[62]. Non-relapse 
mortality was highest for double CB (34%), compared 
with matched related donor (24%), matched unrelated 
donor (14%), or mismatched unrelated donor (27%)[62]. 
However, the risk of  relapse was lowest in recipients of  
double CB (15%), compared with matched related donor 
(43%), matched unrelated donor (37%), or mismatched 
unrelated donor (35%)[62]. The risks of  grade 2-4 acute 
GVHD and chronic GVHD were also the lowest for 
double CB (60% and 26%), compared with matched 
related donor (65% and 47%), matched unrelated donor 
(80% and 43%), or mismatched unrelated donor (85% 
and 48%)[62].
Another study on 367 patients with hematological 
malignancies after myeloablative or non-myeloablative 
conditioning found that 2-year overall survival, progres-
sion-free survival, TRM and grade 2-4 acute GVHD were 
not significantly different in double CB transplant (65%, 
55%, 25% and 43%) as compared to related donor trans-
plant (70%, 66%, 15%, and 27%) and unrelated donor 
transplant (62%, 55%, 27%, and 39%)[63]. However, late 
acute or chronic GVHD was significantly lower in double 
CB transplant (28%) as compared to related donor trans-
plant (31%) and unrelated donor transplant (44%)[63].
A third study compared double CB transplant with 
9/10 mismatched unrelated donor BM or PBSC trans-
plants with reduced intensity conditioning for patients 
with hematological malignancies and found that double 
CB transplant was associated with lower incidence of  
extensive chronic GVHD at 2 years compared with unre-
lated donor transplant (6.4% vs 21.4%)[64]. However, both 
groups were comparable for 2-year overall survival (47.9% 
vs 52.3%), progression-free survival (43.3% vs 38.3%), 
TRM (26% vs 24.2%), relapse (34.3% vs 37.6%), grade 3-4 
acute GVHD (19.1% vs 21.4%), and neutrophil engraft-
ment time (median 17 vs 16 d)[64].
There were 3 studies comparing double CB transplant 
with unrelated donor PBSC transplants after reduced in-
tensity conditioning for adult patients with hematological 
malignancies. The study by Le Bourgeois found that the 
2 groups had similar 2-year overall survival (61% vs 62%), 
disease-free survival (50.5% vs 59.0%), relapse incidence 
(23.0% vs 35.5%), cumulative incidences of  engraftment, 
grade 2-4 acute and chronic GVHD[65]. However, double 
CB recipients had significantly higher median time to 
platelet recovery (38 vs 0 d), early mortality before day 
+100 (20.5% vs 4.0%), and 2-year TRM (26.5% vs 6.0%) 
compared with PBSC recipients[65]. The presence of  a 
lymphoid disorder was associated with a significantly 
higher overall survival[65]. The study by Chen found that 
the 3-year overall survival and progression-free survival 
were comparable between double CB and PBSC trans-
plant (46% vs 50% and 30% vs 40%, respectively), but the 
cumulative incidence of  TRM was significantly higher in 
double CB transplant (26.9% vs 10.4%)[66]. The cumulative 
incidence of  grade 2-4 acute GVHD was not significantly 
different but the 2-year cumulative incidence of  chronic 
GVHD was significantly lower in double CB transplant 
compared with PBSC transplant (21.9% vs 53.9%)[66]. 
The study by Jacobson found that there was no signifi-
cant difference between double CB transplant and PBSC 
transplant in 2-year overall survival (66% vs 68%), pro-
gression-free survival (49% vs 57%), TRM (11% vs 11%), 
relapse (40% vs 32%) and grade 2-4 acute GVHD (21% 
vs 12%)[67]. Double CB recipients had significantly more 
infections (69% vs 33%), both viral (29% vs 1%) and bac-
terial (50% vs 8%) infections, but significantly less chronic 
GVHD (24% vs 54%)[67]. Reconstitution of  T cells was 
significantly delayed in double CB recipients compared 
with PBSC recipients for 1-6 mo post-transplant, includ-
ing naive and memory CD4+ T cells, regulatory T cells, 
and CD8+ T cells[67]. In contrast, B cells recovered more 
rapidly in double CB recipients and B cell number re-
mained significantly greater at 3-24 mo post-transplant[67]. 
Natural killer (NK) cells also recovered more rapidly in 
double CB recipients and remained significantly greater 
at 1-24 mo post-transplant[67].
Haploidentical donor
HLA-haploidentical related donor is an important alter-
native if  no matched related donor is available[68]. Either 
PBSC or BM can be the stem cell source for haploi-
dentical transplant. Positive selection of  CD34+ stem 
cells from harvested PBSC and infusion of  high doses 
of  stem cells successfully overcame HLA barrier with 
good engraftment rate and low incidence of  GVHD[69-78]. 
Leukemia-free survivals and relapses were better in trans-
plants performed in larger centers[79], and in transplants 
with natural killer cell killer immunoglobulin like recep-
tor (KIR) mismatch[80]. However, infection risk was high 
as immunoreconstitution was slow with purified CD34+ 
cells. Subsequently, negative stem cell selection with 
depletion of  CD3+ T cells with or without depletion of  
CD19+ B cells achieved similar success of  engraftment 
without excessive GVHD, with myeloablative or reduced 
intensity conditioning[81-85]. Immune recovery with this 
method was notably faster with reduced infections[81,85,86]. 
Unmanipulated T cell replete PBSC and/or BM products 
could also achieve reasonably good results with intensive 
GVHD prophylaxis or post-transplant cyclophospha-
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mide, despite presence of  large amount of  T cells[87-96]. 
A non-randomized comparative study of  T cell depleted 
with T cell replete haploidentical transplants for adult 
patients with hematological malignancies found that T 
cell replete transplant resulted in significantly better 1-year 
overall survival (64% vs 30%), progression-free survival 
(50% vs 21%), lower TRM (16% vs 42%), chronic GVHD 
(7% vs 18%), and infections, with better reconstitution of  
T cell subsets[97].
Evolving modifications might further improve out-
comes of  haploidentical HSCT, such as post-transplant 
CD8-depleted donor lymphocyte infusion, which could 
promote immune reconstitution[98]. Post-transplant infu-
sion of  regulatory T cells could also promote lymphoid 
reconstitution with improved immunity to opportunistic 
pathogens, while preventing GVHD in the absence of  
any post-transplant immunosuppression, and preserv-
ing the graft-versus-leukemia effect[99,100]. Coinfusion of  
mesenchymal stromal cells could facilitate engraftment 
without increasing leukemia recurrence after haploidenti-
cal HSCT[101,102]. Combining PBSC and BM might also 
improve engraftment, and reduce TRM[103] and relapse[104]. 
Suicide-gene-engineered donor lymphocytes might accel-
erate immune reconstitution while limiting GVHD[105-107]. 
Selective photodepletion of  alloreactive T cells could 
also enhance immunoreconstitution while preventing 
GVHD[108]. Ex vivo induction of  anergy to recipient al-
loantigen by costimulation blockade was another strategy 
to limit GVHD[109]. Depletion of  T cell receptor alpha-
beta positive T cells while retaining gammadelta T cells 
may reduce GVHD while preserving anti-infective and 
anti-tumor effects[110]. A two-step approach in which the 
lymphoid and myeloid portions of  the graft are given in 
two separate steps to control and optimize T cell dosing 
may further improve results with robust immunorecon-
stitution, low GVHD and better disease control[111,112].
There are some non-randomized studies comparing 
haploidentical PBSC or BM transplants with other types 
of  donor or stem cell source. The Blood and Marrow 
Transplant Clinical Trials Network conducted 2 mul-
ticentre trials for patients with leukemia or lymphoma 
undergoing reduced intensity conditioning allogeneic 
transplants and found that haploidentical transplant and 
double CB transplant had comparable 1-year overall sur-
vival (62% vs 54%), 1-year progression-free survival (48% 
vs 46%), neutrophil engraftment (96% vs 94%), and grade 
2-4 acute GVHD (32% vs 40%)[113]. One-year cumulative 
TRM was lower in haploidentical transplant compared 
with double CB transplant (7% vs 24%), but relapse rate 
was higher (45% vs 31%)[113].
CONCLUSION
In conclusion, existing high level evidence suggest that 
there is no significant advantage of  PBSC over BM in 
HLA-matched sibling transplant for patients with hema-
tological malignancies. PBSC transplant probably results 
in lower risk of  relapse and hence better disease-free sur-
vival, especially in patients with high risk or late stage dis-
ease at the expense of  higher risks of  both severe acute 
and chronic GVHD. Existing data are insufficient or 
inconclusive for firm conclusions in specific subgroups 
such as a particular disease entity, conditioning regimen 
or in children. High level evidence is scarce in the unre-
lated donor setting. The only RCT available suggests that 
PBSC and BM result in comparable overall and disease-
free survivals in patients with hematological malignancies; 
and PBSC transplant results in lower risk of  graft failure 
but higher risk of  chronic GVHD. High level evidence 
is lacking for CB in comparison to BM or PBSC. The 
risks and benefits of  different sources of  stem cells likely 
change with different conditioning regimen, strategies 
for prophylaxis and treatment of  GVHD and manipula-
tion of  grafts. The recent success and rapid advance of  
double CB transplant and haploidentical BM and PBSC 
transplants further complicate the selection of  optimal 
stem cell source. Novel therapies for treatment and pro-
phylaxis of  GVHD also minimize the key differences be-
tween stem cell sources. Advances in graft manipulation 
and cellular therapies might change the whole paradigm 
making stem cell source selection less critical, e.g., stem 
cell enrichment could facilitate engraftment, specific and 
highly selective depletion of  certain lymphocyte subsets 
and alloreactive cells could minimize GVHD, infusion of  
mesenchymal stem cells could facilitate engraftment and 
reduce GVHD, titrated T cell dosing and NK cell therapy 
might reduce relapse. Detailed counseling of  patient and 
donor regarding risks and benefits in the specific context 
of  the patient and transplant method is of  paramount 
importance for informed decision making.
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